Targeted Alpha Radionuclide Therapy (TAT)-Ac-225 Radiopharmaceuticals; [Hedefe Yönelik Alfa Radyonüklid Tedavisi (TAT)-Ac-225 Radyofarmasötikleri]
Küçük Resim Yok
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Galenos Publishing House
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Targeted alpha therapy (TAT) has become increasingly popular in recent years due to its easy application in patients with multiple metastases, its ability to treat multiple lesions simultaneously, and its ability to be used in combination with other treatment methods. TAT is performed by chelate conjugated-targeting molecules such as small peptides, peptidomimetics, monoclonal antibodies, biomolecules and small inhibitor molecules tagged with alpha-emiting radionuclides. It is possible to obtain Actinium-225 in various ways. The majority of Ac-225 used for preclinical research and clinical administration is radiochemically isolated from build-up sources of thorium-229. © 2023 The authors.
Açıklama
Anahtar Kelimeler
Ac-225, Ac-225 radiopharmaceuticals, Targeted alpha therapy
Kaynak
Nuclear Medicine Seminars
WoS Q Değeri
Scopus Q Değeri
N/A
Cilt
9
Sayı
1
